KẾT QUẢ ĐIỀU TRỊ HÓA CHẤT BỔ TRỢ TRƯỚC PHẪU THUẬT PHÁC ĐỒ 4AC-4T LIỀU DÀY BỆNH UNG THƯ VÚ TẠI BỆNH VIỆN ĐẠI HỌC Y HÀ NỘI

Abstract

Objectives: Our study aims to describe the clinical and paraclinical characteristics of breast cancer patients and evaluate the treatment outcomes and toxicity of neoadjuvant dose dense 4AC- 4T regimen in this group. Patients and Methods: Retrospective and prospective, descriptive study on 42 patients with breast cancer, were treated with neoadjuvant dose dense 4AC-4T regimen at Hanoi Medical University Hospital. Results: The mean age was 46,5. The majority of them were in stage III (81%) while  19% patients were in stage II. 92,9% patients’s histology were invasive carcinoma of no special type (NST) and 50% was in grade III. After treatment, the  complete clinical response rised from 11,9% (after 4 cycles of AC) to 38,1% (after 8 cycles of 4AC- 4T). No patient progressed during      8 cycles. All of our patients were moved to modified radical mastectomy after neoadjuvant chemotherapy. The pathological complete response (pCR) rate was 42,8%. Most adverse events were  manageable and tolerable. The most common toxicity was neutropenia with grade 1,2. Non hematological toxicities such as vomiting, fatigue, alopecia and neurotoxity were also common and all of them were mild and moderate. Conclusion: Dose dense 4AC-4T regimen in neoadjuvant setting gives a high pCR rate with tolerable tocxicity, therefore this regimen can be widely used as neoadjuvant chemotherapy prior to surgery in our country, specilly with inoperable stage at initial diagnosis.